For research use only. Not for therapeutic Use.
MRS2964（Cat No.:I032779）is a selective, potent antagonist of the P2Y1 receptor, a subtype of purinergic receptors that are activated by adenosine-5′-diphosphate (ADP). The P2Y1 receptor is involved in platelet aggregation, vascular smooth muscle contraction, and various other physiological processes, making it a target for thrombotic disorders. By blocking P2Y1 receptors, MRS2964 is being investigated for its potential in preventing platelet aggregation, which could be beneficial in treating conditions like thrombosis and stroke. The compound has shown promise in preclinical studies as a therapeutic agent to modulate platelet function and reduce thrombotic risks.
| Catalog Number | I032779 |
| Synonyms | MRS-2964; MRS 2964; MRS2964 |
| Molecular Formula | C16H30N6O12P2 |
| Purity | 98% |
| Solubility | Soluble in DMSO |
| Appearance | Solid powder |
| Storage | Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years). |
| IUPAC Name | triazanium;[[(2R,3S,4R,5R)-3,4-dihydroxy-5-[2-oxo-4-(phenylmethoxyamino)pyrimidin-1-yl]oxolan-2-yl]methoxy-oxidophosphoryl] phosphate |
| InChI | InChI=1S/C16H21N3O12P2.3H3N/c20-13-11(9-29-33(26,27)31-32(23,24)25)30-15(14(13)21)19-7-6-12(17-16(19)22)18-28-8-10-4-2-1-3-5-10;;;/h1-7,11,13-15,20-21H,8-9H2,(H,26,27)(H,17,18,22)(H2,23,24,25);3*1H3/t11-,13-,14-,15-;;;/m1.../s1 |
| InChIKey | XBKBDADHWFHGGG-GXYUULLCSA-N |
| SMILES | C1=CC=C(C=C1)CONC2=NC(=O)N(C=C2)[C@H]3[C@@H]([C@@H]([C@H](O3)COP(=O)([O-])OP(=O)([O-])[O-])O)O.[NH4+].[NH4+].[NH4+] |
| Reference | 1: Maruoka H, Barrett MO, Ko H, Tosh DK, Melman A, Burianek LE, Balasubramanian R, Berk B, Costanzi S, Harden TK, Jacobson KA. Pyrimidine ribonucleotides with enhanced selectivity as P2Y(6) receptor agonists: novel 4-alkyloxyimino, (S)-methanocarba, and 5′-triphosphate gamma-ester modifications. J Med Chem. 2010 Jun 10;53(11):4488-501. doi: 10.1021/jm100287t. PubMed PMID: 20446735; PubMed Central PMCID: PMC2935147. |
